Solid Tumor Clinical Trial
Official title:
The Good Patient Study
Adolescents with cancer weigh multiple influences in medical decision-making, including
their own best interest, the perceived wishes of family members, and the interpreted
preferences of the health care team. Parents of children with cancer often describe
themselves as trying to be a good parent in making decisions in the child's best interest.
Adolescents with cancer often describe themselves as trying to be a good patient and good
child in making decisions in accord with how they believe a good patient and good child
would decide.
Among the challenges of caring for adolescents is the reality that the formative relational
influences in adolescents' decision-making are both complex and unique due to adolescent
patients' social networks and relational roles. Delineating adolescents' definitions of
being a good patient, a good child, a good sibling, and a good friend may enable the care
team to better understand the formative decisional influences relevant to adolescents with
cancer. Expanding knowledge about the decision making constructs relevant to adolescents
with cancer and recognizing the role of these social constructs in medical interactions has
the potential for development of a comprehensive care model that methodically evaluates the
self-assessed decision making influences and needs of adolescents at various stages in
oncology care.
This qualitative construct-defining study represents an initial step in the development of
enhanced interventions for improved psychosocial support in this vulnerable population.
Status | Completed |
Enrollment | 43 |
Est. completion date | May 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years to 19 Years |
Eligibility |
Inclusion Criteria: - Participants must be between 12 and 19 years of age at the time of enrollment. - Participants must have primary care team approval to participate. - Participants must be English-speaking. - Participants must carry an oncologic diagnosis. - Participants must be within four months of initial oncologic diagnosis or within four months of relapse/recurrent disease. Exclusion Criteria: - This study lacks any exclusion related to pregnancy (an Institutional Review Board requirement for enrollment of females who are capable of becoming pregnant), lactation or plans to become pregnant and lacks any exclusion of males fathering children while on study. - Patients who, in the opinion of their physician, are not capable mentally or verbally of participating in the interview, will be excluded from the study. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | Children's National Health System | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Factors contributing to decision-making | Describe the ways relationships and social interactions may factor into adolescent study participants' approach to decisions. | Once, at enrollment | No |
Primary | Behaviors that make a positive impact on decision-making | By reports from adolescents with cancer, identify behaviors from members of the study participants' social network that would be helpful to adolescents in fulfilling their preferred role in medical decision-making and achieving the desired level of participation in medical decision-making. | Once, at enrollment | No |
Primary | Preferred decision-making role | Identify adolescent participants' preferred role in medical decision making. | Once, at enrollment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |